Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity
暂无分享,去创建一个
[1] P. S. Sørensen,et al. Management of patients with neutralizing antibodies against interferon‐beta: stop IFN‐beta therapy or wait for the antibodies to go away? , 2009, European journal of neurology.
[2] A. Oturai,et al. Gene expression analysis of interferon-β treatment in multiple sclerosis , 2008, Multiple sclerosis.
[3] H. Salamon,et al. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[4] E. Buchberger,et al. Neutralizing Type I IFN Antibodies Trigger an IFN-Like Response in Endothelial Cells1 , 2008, The Journal of Immunology.
[5] P. Valentino,et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis , 2008, Neurology.
[6] D. Miller,et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta , 2008, Multiple sclerosis.
[7] P. S. Sørensen,et al. Using measurements of neutralizing antibodies: the challenge of IFN‐β therapy , 2007 .
[8] D. Goodin,et al. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED] , 2007, Neurology.
[9] P. Sorensen,et al. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. , 2007, European journal of neurology.
[10] C. Polman,et al. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. , 2007, Neurology.
[11] P. Sørensen,et al. Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS , 2006, Neurology.
[12] K. Narayan,et al. Multiplex analysis of expression of three IFNβ-induced genes in antibody-positive MS patients , 2006, Neurology.
[13] K. Bendtzen,et al. Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis , 2006, Multiple sclerosis.
[14] C. Pozzilli,et al. Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis , 2005, European journal of neurology.
[15] K. Narayan,et al. The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies , 2005, Journal of Neuroimmunology.
[16] P. Sørensen,et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy , 2005, Neurology.
[17] K. Narayan,et al. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. , 2005, Journal of neuroimmunology.
[18] A. Bertolotto,et al. Cotugno and cerebrospinal fluid , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[19] P. Sørensen,et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis , 2003, The Lancet.
[20] Murali Ramanathan,et al. Genomic Effects of IFN-β in Multiple Sclerosis Patients 1 , 2003, The Journal of Immunology.
[21] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] R. Lindberg,et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients , 2003, Neurology.
[23] Murali Ramanathan,et al. Genomic effects of IFN-beta in multiple sclerosis patients. , 2003, Journal of immunology.
[24] D S Goodin,et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines , 2002, Neurology.
[25] S. Grossberg,et al. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[26] M. Reindl,et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies , 1999, Neurology.
[27] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .